Belite Bio (NASDAQ:BLTE) Stock: Insider Hendrik Peter Scholl Sells 2,000 Shares

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE – Get Free Report) insider Hendrik Scholl sold 2,000 shares of Belite Bio stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $165.99, for a total value of $331,980.00. Following the sale, the insider owned 12,500 shares of the company’s stock, valued at approximately $2,074,875. This represents a 13.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Hendrik Peter Scholl also recently made the following trade(s):

  • On Thursday, October 1st, Hendrik Scholl sold 500 shares of Belite Bio stock. The shares were sold at an average price of $165.32, for a total value of $82,660.00.

Belite Bio Price Performance

NASDAQ:BLTE traded down $1.79 during mid-day trading on Monday, reaching $162.56. The stock had a trading volume of 191,275 shares, compared to its average volume of 173,816. The business’s 50 day moving average is $160.26 and its 200 day moving average is $160.22. Belite Bio, Inc. Sponsored ADR has a fifty-two week low of $105.88 and a fifty-two week high of $200.00. The stock has a market cap of $6.55 billion, a P/E ratio of -59.55 and a beta of -1.19.

Belite Bio (NASDAQ:BLTE – Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.79) by $0.19. Equities analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.08 EPS for the current year.

Institutional Investors Weigh In On Belite Bio

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in Belite Bio by 5.0% during the third quarter. GAMMA Investing LLC now owns 1,771 shares of the company’s stock worth $301,000 after purchasing an additional 85 shares during the period. Royal Bank of Canada raised its position in shares of Belite Bio by 7.9% in the first quarter. Royal Bank of Canada now owns 2,257 shares of the company’s stock valued at $360,000 after purchasing an additional 165 shares during the period. Engineers Gate Manager LP raised its position in shares of Belite Bio by 11.4% in the second quarter. Engineers Gate Manager LP now owns 2,773 shares of the company’s stock valued at $427,000 after purchasing an additional 284 shares during the period. Vise Technologies Inc. bought a new position in shares of Belite Bio in the third quarter valued at approximately $217,000. Finally, Bank of America Corp DE raised its position in shares of Belite Bio by 104.0% in the first quarter. Bank of America Corp DE now owns 3,778 shares of the company’s stock valued at $602,000 after purchasing an additional 1,926 shares during the period. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BLTE. Mizuho raised their price target on shares of Belite Bio from $221.00 to $230.00 and gave the company an “outperform” rating in a report on Monday. Morgan Stanley upped their price objective on shares of Belite Bio from $201.00 to $206.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Canaccord Genuity Group upped their price objective on shares of Belite Bio from $303.00 to $314.00 and gave the stock a “buy” rating in a report on Monday. Zacks Research downgraded shares of Belite Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a report on Friday, October 2nd. Nine investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $226.91.

View Our Latest Report on Belite Bio

Belite Bio Company Profile

(Get Free Report)

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

Featured Stories

Insider Buying and Selling by Quarter for Belite Bio (NASDAQ:BLTE)

Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.